VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update
VolitionRx Limited Schedules Third Quarter 2017 Earnings Conference Call and Business Update
VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits
VolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding
VolitionRx Announces its European Colorectal Cancer Strategy
VolitionRx to Attend Two Major Conferences in Asia
Volition Granted Four Additional Patents
VolitionRx Limited to Attend Multiple Conferences in September
Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers
VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update
